Challenge:

Increasing payer awareness and facilitating informed coverage decisions are critical in the CGT sector, particularly as these innovative treatments compete for priority and reimbursement alongside well-established therapies in some cases. Payers must navigate the intricacies of evaluating CGTs, which often involve high upfront costs but may have long-term value and potentially curative benefits. This requires a deep understanding of the unique clinical and economic profiles of CGTs compared to existing treatment options.

Payers are beginning to indicate that CGTs coming to market for conditions for which one or more CGTs are already approved to treat the same target patient population may face more scrutiny in coverage.¹ This can create barriers to coverage as insurers and healthcare systems work to evaluate and differentiate therapies.

Recommendation: 

Manufacturers should evaluate the use of appropriate pre-approval communication with payers, providing robust evidence of clinical safety, efficacy, and cost-effectiveness.

Upon FDA approval, manufacturers should deploy post-approval communications to address potential access barriers such as cost, long-term durability, complex patient and product journeys, and patient portability across state lines for administration of therapy.

Challenge: 

Many CGTs are beginning to treat larger patient populations, whether because of the prevalence of the disease or by positioning the treatment earlier in the treatment pathway. For disease states with broader patient populations as well as earlier-line therapies that open more eligibility to patients in the treatment funnel, payers will seek to understand the impact on their book of business.

Innovative pricing and reimbursement models are becoming a pressing payer budgetary consideration to address. The high upfront cost of CGTs necessitates creative financial options that address affordability and accessibility while maintaining economic viability for manufacturers.

Recommendation:

Manufacturers should demonstrate the economic value of their therapy in addition to the clinical value, given that treating earlier-line patients may provide larger offset costs if chronic comorbidities and treatment/symptom management failures may be reduced or avoided altogether.

Fostering partnerships with healthcare providers and payers to create integrated care pathways can help streamline the administration and monitoring processes, so that logistical hurdles are minimized. By implementing these strategies, manufacturers can facilitate the transition of CGTs into earlier treatment lines, with the goal of enhancing their
accessibility and impact on patient outcomes.

Collaborating with payers to develop innovative pricing arrangements, supported by comprehensive data on long-term benefits and cost-effectiveness, can also help facilitate broader adoption and integration of CGTs into mainstream healthcare.

Challenge: 

Transitioning CGT administration from inpatient to outpatient settings presents both challenges and opportunities for patients, healthcare providers, and payers, including:

• From a patient perspective, the shift could negatively impact patient out-of-pocket costs because outpatient services often involve different cost-sharing arrangements than inpatient care. Payers may need to help address these disparities to prevent financial barriers to access.
• From a provider perspective, this transition requires adaptations in infrastructure, training, and patient management protocols. The network of Centers of Excellence will likely evolve from mostly academic institutions to include community and office settings. This leads to different logistical and administration considerations, as well as reimbursement structures for the providers and facilities.
• Payers may implement stricter utilization management protocols, such as prior authorization or step therapy, to control access and ensure appropriate use. These measures aim to manage costs while maintaining quality care. Additionally, payers will increasingly rely on real-world data to assess long-term outcomes and effectiveness. This data is vital for maintaining flexible and informed coverage decisions as therapies evolve.

This evolution in treatment models is driven by therapeutic innovation leading to strong safety profiles, the need to improve patient convenience, a push to reduce healthcare costs, and the common desire to expand patient access.

Recommendation:

Manufacturers need to prepare for the evolution of payers’ management strategies as they seek to balance cost, access, and quality outcomes. Manufacturers should be forward-looking and support the appropriate education, infrastructure, and logistics, especially concerning storage and administration. This includes partnering to develop specialized centers and training healthcare professionals to handle the unique aspects of these therapies.

Clarity on the reimbursement pathway is also essential for manufacturers to appropriately support because outpatient treatments often demand different payment structures compared to inpatient care. This transition is poised to enhance accessibility and affordability for a wider range of patients, but it also compels stakeholders to navigate regulatory, operational, and economic hurdles to provide successful implementation and equitable access.